Helen X Chen
Affiliation: National Institutes of Health
- IGF-1R as an anti-cancer target--trials and tribulationsHelen X Chen
National Cancer Institute, Bethesda, MD 20892, USA
Chin J Cancer 32:242-52. 2013..While IGF-1R remains a valid target for selected tumor types, identification of predictive markers and rational combinations will be critical to success in future development...
- Adverse effects of anticancer agents that target the VEGF pathwayHelen X Chen
Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD 20851, USA
Nat Rev Clin Oncol 6:465-77. 2009..This Review examines the toxicity profiles of anti-VEGF antibodies and small-molecule inhibitors. The potential mechanisms of the adverse effects, risk factors, and the implications for selection of patients and management are discussed...
- Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activityNilofer S Azad
Medical Oncology Branch, Biostatistics and Data Management Section, and Genetics Branch, Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA
J Clin Oncol 26:3709-14. 2008..Bevacizumab is a monoclonal antibody targeted against VEGF. We hypothesized that the complementary inhibition of VEGF signaling would have synergistic therapeutic effects...
- Expanding the clinical development of bevacizumabHelen X Chen
Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Oncologist 9:27-35. 2004..Treatment regimens being examined include bevacizumab alone and in combination with conventional chemotherapy, radiation, immune therapy, and biologically targeted agents...
- Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirementsShivanni Kummar
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
Nat Rev Drug Discov 9:843-56. 2010....
- Clinical development of antisense oligonucleotides as anti-cancer therapeuticsHelen X Chen
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
Methods Mol Med 75:621-36. 2003
- Strategies for optimizing combinations of molecularly targeted anticancer agentsJanet E Dancey
Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard EPN 7131, Rockville, Maryland 20852, USA
Nat Rev Drug Discov 5:649-59. 2006..Issues that pose challenges to the rational preclinical and clinical evaluation of such combinations will be described, and possible approaches to overcoming these challenges will be discussed...
- Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301Helen X Chen
Cancer Treatment Evaluation Program, National Cancer Institute, Bethesda, MD 20892, USA
J Clin Oncol 24:3354-60. 2006....
- A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerJames C Yang
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
N Engl J Med 349:427-34. 2003..We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma...
- Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trialArun Rajan
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
Lancet Oncol 15:191-200. 2014..We investigated the efficacy of cixutumumab, a fully human IgG1 monoclonal antibody targeting the insulin-like growth factor 1 receptor in thymic epithelial tumours after failure of previous chemotherapy...